跳至主要内容
临床试验/ISRCTN46087965
ISRCTN46087965已完成1 期

Phase I/II clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome

Genethon (France)0 个研究点目标入组 5 人开始时间: 2011年5月20日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
5

研究概览

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Males of all ages
  • 2. Severe WAS (clinical score 3 ? 5) or absence of WAS protein in peripheral blood mononuclear cells determined by Western blotting and flow cytometry
  • 3. Molecular confirmation by WAS gene DNA sequencing
  • 4. Lack of HLA-genotypically identical bone marrow or of a 10/10 antigen HLA-matched unrelated donor or cord blood after 3 month search
  • 5. Parental, guardian, patient signed informed consent/assessment
  • 6. Willing to return for follow-up during the 2 year study and the 3 year long-term off study review
  • 7. Only for patients who have received previous allogenic haematopoietic stem cell transplant:
  • 7.1. Failed allogenic haematopoietic stem cell transplant
  • 7.2. Contraindication to repeat allogeneic transplantation for example severe graft versus host disease

排除标准

  • 1. Patient with HLA-genotypically identical bone marrow
  • 2. Patient with 10/10 antigen HLA-matched unrelated donor or cord blood
  • 3. Contraindication to leukapheresis
  • 3.1. Anaemia (Hb < 8g/dl)
  • 3.2. Cardiovascular instability
  • 3.3. Severe coagulopathy
  • 3.3.1. Contraindication to bone marrow harvest
  • 3.3.2. Contraindication to administration of conditioning medication
  • 3. Human immunodeficiency virus (HIV) positive patient

研究者

发起方
Genethon (France)

相似试验